Besides, fulvestrant+ CDK4/6 inhibitor is recommended as a preferred regimen for the second-line and subsequent therapy of HER2-negative ER- and/or PR-positive recurrent or stage IV breast cancer by NCCN guideline 2020. Here, ERBB2 is linked to breast carcinoma.